Z79.810 — Long term (current) use of selective estrogen receptor modulators (SERMs)
Is Z79.810 billable?
Yes — Z79.810 is billable for FY2027. Z79.810 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. Z79.810 may be submitted for encounters from October 1, 2026 through September 30, 2027.
Z79.810 at a glance
| Code | Z79.810 |
|---|---|
| Description | Long term (current) use of selective estrogen receptor modulators (SERMs) |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
What Medicare edits apply to Z79.810?
The Medicare Code Editor screens inpatient claims before they are grouped. These edits name Z79.810 directly.
CMS will reject this code as the principal diagnosis on an inpatient claim. It describes something other than the condition chiefly responsible for the admission.
Which MS-DRGs does Z79.810 group to?
Z79.810 sits in MDC 23 and helps define the logic of 1 MS-DRG (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 951Other Factors Influencing Health Statusmedical
How is Z79.810 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to Z79.810. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Long-term › Evista (current) (prophylactic) drug therapy (use of)
- Long-term › Fareston (current) (prophylactic) drug therapy (use of)
- Long-term › Nolvadex (current) (prophylactic) drug therapy (use of)
- Long-term › raloxifene (current) (prophylactic) drug therapy (use of)
- Long-term › selective estrogen receptor modulators (current) (prophylactic) drug therapy (use of)
- Long-term › tamoxifen (current) (prophylactic) drug therapy (use of)
- Long-term › toremifene (current) (prophylactic) drug therapy (use of)
- Therapy › drug, long-term › Evista
- Therapy › drug, long-term › Fareston
- Therapy › drug, long-term › Nolvadex
- Therapy › drug, long-term › raloxifene
- Therapy › drug, long-term › selective estrogen receptor modulators
Inclusion terms
Alternative wording in documentation that is classified to Z79.810.
- Long term (current) use of raloxifene (Evista)
- Long term (current) use of tamoxifen (Nolvadex)
- Long term (current) use of toremifene (Fareston)
Excludes1 — never code together — inherited from Z79.81
The conditions below can never be reported together with Z79.810 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
- hormone replacement therapy (Z79.890)
Code first — inherited from Z79.81
The underlying condition below must be sequenced before Z79.810. Z79.810 describes a manifestation and cannot be the principal or first-listed diagnosis.
Use additional code — inherited from Z79.81
Report an additional code alongside Z79.810 to fully describe the condition. Z79.810 is sequenced first.
Excludes2 — not included here — inherited from Z79
The conditions below are not part of Z79.810, but a patient may have both at the same time. When documentation supports it, Z79.810 and the excluded code may both be reported.
Code also — inherited from Z77-Z99
Two codes may be needed to describe the condition fully. Whether Z79.810 is sequenced first depends on the reason for the encounter.
- any follow-up examination (Z08-Z09)
Code also — inherited from Z79
Two codes may be needed to describe the condition fully. Whether Z79.810 is sequenced first depends on the reason for the encounter.
- any therapeutic drug level monitoring (Z51.81)
How long has Z79.810 existed?
Z79.810 has been in ICD-10-CM since at least FY2016, the earliest fiscal year on record here.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.